Discussion about this post

User's avatar
Barbara Wei's avatar

Nice summary! After 9 years in the pharma commercialization industry, I'd like to add that sometimes Phase II/III occur together for rare diseases since it takes so long and is so hard to enroll all patients. Data releases from P2 and P3 are huge days for pharma companies.

Expand full comment
1 more comment...

No posts